CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani by Verma, Smriti et al.
CYP5122A1, a Novel Cytochrome P450 Is Essential for
Survival of Leishmania donovani
Smriti Verma, Ashish Mehta¤, Chandrima Shaha*
Cell Death and Differentiation Research Laboratory, Centre for Molecular Medicine National Institute of Immunology, New Delhi, India
Abstract
Background: Cytochrome P450s (CYP450s) are hemoproteins catalysing diverse biochemical reactions important for
metabolism of xenobiotics and synthesis of physiologically important compounds such as sterols. Therefore, they are
functionally important for survival of invading pathogens. One such opportunistic pathogen Leishmania donovani causes
visceral leishmaniasis worldwide, which is an important public health problem due to significant disease burden. The
parasite genome database, Gene DB, annotates 3 CYP450s in Leishmania, however, the functional role of cytochrome P450
enzymes in Leishmania spp. remains elusive.
Methodology/Principal Findings: A CYP450-like gene cloned from Leishmania donovani was identified as a novel CYP450,
the CYP5122A1. Upon co-localization with organelle specific markers, CYP5122A1 distribution was shown to be localized in
the promastigote ER, mitochondria and the glycosomes. Replacement of one allele of CYP5122A1 with either neomycin or
hygromycin gene by homologous recombination in Leishmania promastigotes induced substantial reduction of CYP5122A1
expression. These parasites showed impaired growth, lower mitochondrial Ca2+ and membrane potential resulting in low
ATP generation. Also, these parasites were less infective in vitro and in vivo than their wild-type counterparts as assessed by
incubation of Leishmania promastigotes with macrophages in vitro as well as through administration of parasites into
hamsters. The HKOs were more susceptible to drugs like miltefosine and antimony, but showed reduced sensitivity to
amphotericin B. Removal of two alleles of CYP5122A1 did not allow the parasites to survive. The mutant parasites showed
3.5 times lower ergosterol level as compared to the wild-type parasites when estimated by Gas chromatography/mass
spectrometry. Complementation of CYP5122A1 through episomal expression of protein by using pXG-GFP+2 vector
partially rescued CYP5122A1 expression and restored ergosterol levels by 1.8 times. Phenotype reversal included restored
growth pattern and lesser drug susceptibility.
Conclusions/Significance: In summary, this study establishes CYP5122A1 as an important molecule linked to processes like
cell growth, infection and ergosterol biosynthesis in Leishmania donovani.
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Introduction
For survival within host cells, parasites are required to eliminate
host generated oxidative stress products, maintain biosynthesis of
essential molecules and resist lethal drugs. Leishmania donovani, a
kinetoplastid parasite, causes visceral leishmaniasis (VL) in humans
and the disease remains a significant problem in the tropics due to
emergence of drug resistance [1]. This situation is compounded by
overlap of endemic regions of VL with regions of HIV infection
where the opportunistic pathogen Leishmania presents a major
problem [2]. Leishmania parasites have a digenetic life cycle where
infectious metacyclic promastigotes differentiate within the sand
fly and following transfer to the mammalian host through sandfly
bite, the parasites thrive as non-motile amastigotes within the
macrophages [1,3] Earlier studies from this laboratory and others
have shown that both the promastigote and the amastigote forms
of Leishmania donovani are sensitive to oxidative and nitrosative stress
and use specialized defense systems unique to themselves to
survive when exposed to such conditions [4–7]. In the absence of
an effective vaccine, limited chemotherapeutic drugs and growing
drug resistance, it has become important to increase the
understanding of the physiology of the Leishmania parasite to
explore for new drug targets. Although several aspects of
Leishmania cellular defense are known, the role of CYP450-like
proteins in the survival of this parasite remains to be explored.
CYP450s are hemoproteins catalysing a variety of chemical
reactions including biotransformation of drugs, bioconversion of
xenobiotics, chemical carcinogen metabolism and the synthesis of
physiologically important compounds such as sterols and fatty
acids [8]. A clear indication of CYP450 involvement in Leishmania
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survival comes from studies where CYP450 inhibitors, the azole
antifungals namely itraconazole, ketoconazole and fluconazole,
have been used as successful antileishmanial agents [9]. Azole
antifungals also cause radical parasitological cure in murine
models of Chagas’ disease, caused by a related parasite, the
Trypanosoma cruzi through inhibition of CYP51, a sterol C14 alpha-
demethylase [9–10]. Reportedly, Leishmania cell lysates catalyse
CYP450-like reactions [11]. The above studies clearly indicate a
functional role of CYP450s in kinetoplastid parasite biology;
however, no reports are available on the actual functional
involvement of these molecules. Due to their involvement in
multiple functional systems, CYP450s are potential drug targets as
shown in Mycobacterium tuberculosis [12] and are reportedly
associated with drug resistance in Candida albicans [13].
One of the important functions of CYP450s is biosynthesis of
ergosterol [14] which is the primary component of the Leishmania
membrane and is functionally linked to maintenance of structural
integrity and protection from biotic stress [15]. Therefore,
interference with ergosterol biosynthesis could result in disruption
of parasite function and molecules involved in this pathway could
serve as potential drug targets [16]. Interestingly, Leishmania can
survive altered sterol levels [17] but changes in sterol profile have
been linked to amphotericin B and fluconazole resistance [9,18].
The genome database of the kinetoplastid parasites annotate three
putative CYP450-like proteins amongst the members of the genus
Leishmania and Trypanosoma, however, functional information on
none of the three CYP450-like proteins is available which could
have important role in Leishmania survival related to drug response,
synthesis of biologically important molecules and elimination of
xenobiotics. Therefore, it is important to analyse the function of
Leishmania CYP450s to understand multiple functional aspects of
parasite physiology that contribute to cell survival and drug
resistance.
In this study, we identify CYP5122A1 as a novel CYP450 of
Leishmania donovani playing a role in several important events in
parasite function including response to drugs and the ability to
infect.
Results
CYP5122A1 is well conserved within Leishmania spp.
To probe into the function of one of the CYP450-like proteins
in Leishmania donovani, the gene was cloned using primers designed
from the sequence of its orthologue in L. major (Lmj F27.0090,
Gene DB, Wellcome Trust Sanger Institute, Hinxton, UK). The
sequence of the full length clone (Acc. No. DQ267494) was
classified by the ‘Cytochrome P450 Nomenclature Committee’
[19] as CYP5122A1 (Nelson D.R. at The Cytochrome P450
Homepage, http://drnelson.uthsc.edu/CytochromeP450.html;
personal communication). The CYP5122A1 sequence shared
close identities with CYP450–like proteins of other members of
the Leishmania spp. like Leishmania major, Leishmania infantum,
Leishmania mexicana, Leishmania braziliensis (87–98%) as well as with
the Trypanosoma spp. (50–53%). A phylogenetic tree comparing
CYP5122A1 with CYP450s from other species show Leishmania
CYP450s as a separate cluster from Trypanosoma which is the
closest neighbour, the evolutionary distance from mammals being
large (Fig. S1).
A characteristic feature of P450 superfamily is a high
conservation in their general topology and structural fold despite
low sequence similarity; however, no two CYP450s are structurally
identical [20]. The CYP5122A1 sequence showed the presence of
a transmembrane domain (TM; amino acids 38–60), a proton
transfer groove (PTC; amino acid 348–353), a motif for
stabilization of the core (SC; amino acid 418–421) and a heme
binding loop (HBL; amino acid 516–525) (Fig. 1A) that are
characteristics of CYP450 proteins. Homology modelling attempts
for CYP5122A1 on the RCSB (Research Collaboratory for
Structural bioinformatics) PDB (www.pdb.org/) server identified
several templates of CYP102 (BM-3) usable for homology
modelling of CYP5122A1. One such template 1ZOA generated
a model of CYP5122A1 spanning from 70 to 590 of 592 residues
including the active site heme binding motif containing the
characteristic P450 consensus sequence represented by Phe-Ile-
Asn-Gly-Pro-Arg-Asn-Cys-Leu-Gly (amino acids 516 to 525). The
conserved catalytic cysteine (marked by arrow), a ligand for the
heme iron, occupies position 523 (Fig. 1B, Fig. S2), in the heme
binding loop (Fig. 1A), and is exposed in a pocket just before the L
helix (Fig. 1B; Fig. S2), as is observed in all the cytochrome P450s
in general. The conserved motif for stability of the CYP450s (SC;
Fig. 1A) was represented by Glu-Thr-Leu-Arg (amino acids 418 to
421; Fig. S2) located in the helix K on the proximal side of the
heme binding domain (Fig. 1B, Fig. S2). The proton transfer
groove (PTG; Fig. 1A) containing amino acids Ala-Gly-His-Glu-
Thr-Ser (amino acids 348 to 353; Fig. S2), located on the distal
side of the heme in the central part of I-helix was close to the
substrate binding site (Fig. 1B). The overall packing quality of the
model assessed using WHATCHECK server was within normal
range (z =21.329). Further analysis of the Ramachandran plot of
the same generated by PROCHECK, showed majority (85%) of
amino acids in the highly favourable region (Fig. S3). Therefore,
the above data shows that CYP5122A1 of L. donovani contains
CYP450 consensus sequences and shares close identity with
CYP450 proteins of both the old and the new world Leishmania
spp.
CYP5122A1 shows no major change during
differentiation of metacyclics and is located at different
subcellular locations
Parasite growth and differentiation into infective forms
(metacyclics) within the insect host can be mimicked in vitro by
culturing flagellated promastigotes [21]. To check intracellular
levels of CYP5122A1, a specific antibody raised against the most
immunodominant sequence stretch on CYP5122A1 that recog-
nized a single band in Leishmania donovani whole cell lysates was
used. When the presence of CYP5122A1 in the promastigotes and
the amastigotes was checked, both forms showed the presence of
CYP5122A1, where the total concentration of the protein
appeared to be higher in the amastigotes (Fig. 2A). As shown in
Fig. 2B, no major change in the intracellular CYP5122A1 levels
was observed during differentiation of the metacyclics with the
constitutive levels remaining fairly constant in an unsynchronized
culture (Fig. 2C, bar graph). However, when we looked at protein
levels in metacyclic parasites from logarithmic (day 3) and
stationary phase (day 5), a higher CYP5122A1 protein level was
observed in the metacyclics isolated from stationary phase cultures
(Fig. 2D, lane 2) in comparison to those isolated from log phase
cultures (Fig. 2D, lane 1).
CYP5122A1 was associated with the lipid fraction and not the
aqueous fraction of cell extracts prepared with Triton-X114
(Fig. 3A) suggesting membrane association of the protein which is
in concurrence with the presence of a membrane spanning domain
between amino acids 38–60 (Fig. 1A). Promastigotes from log
phase cultures stained with anti-CYP5122A1 and counter-stained
with BIP, an hsp70 family protein found in ER, and ER Tracker
BlueH, a dapoxyl dye that stains ER in live cells, showed co-
localization of ER and CYP5122A1 stain indicating localization of
the protein to the ER (Fig. 3B, a–e, BIP and ER Tracker blue). In
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addition, although less predominant, co-localization of
CYP5122A1 staining was also seen in the mitochondria identified
using MitoTracker RedH or glycosomes marked with glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (Fig. 3B, a–e, Mito-
Tracker red and GAPDH). Therefore, these observations show
that CYP5122A1 distribution is confined predominantly to the
endoplasmic reticulum and in smaller amounts to the mitochon-
dria and the glycosomes. The metacyclic forms of the parasite
were isolated and stained with anti-CYP5122A1 antibody and
anti-BIP antibody to see if the staining pattern was similar to log
phase promastigotes. Co-localization of CYP5122A1 with BIP was
observed indicating that there was no apparent difference in the
localization of the protein as cells differentiated into metacyclics
(Fig. S7).
CYP5122A1 is essential for optimal growth of the parasite
To determine the importance of CYP5122A1 in the survival of
Leishmania donovani, the CYP5122A1 encoding sequence was
disrupted by ORFs encoding for neomycin or hygromycin
resistance. Gene replacement vectors (pBSK+CYP5122A1Neo or
pBSK+CYP5122A1Hyg) were constructed such that ORFs encod-
ing neomycin/hygromycin resistance were flanked by sequences
homologous to 59 and 39 region of the target gene. These vectors
were used to transform wild-type (WT) cells where homologous
recombination resulted in one allele being replaced by the antibiotic
resistance gene and the resultant parasites had only one functional
allele of CYP5122A1 (half knockout, HKO). These parasites with
one allele of CYP5122A1 were re-transfected with the vectors
containing the second antibiotic resistance gene to obtain
replacement of the remaining allele so that parasites expressing no
CYP5122A1 could be obtained. These double knockout parasites
did not survive in culture suggesting that the gene may be essential
for parasite survival. Therefore, we used the HKOs containing one
allele of CYP5122A1 for further functional experiments. For
characterization of these HKO parasites, the successful deletion
one WT copy of the CYP5122A1 gene was confirmed by PCR with
genomic DNA of the HKOs using primers (primer positions marked
in the schematic, Fig. 4A) for neomycin (Fig. 4B, lane 2), as well as a
forward primer spanning the 59 end of the CYP5122A1 gene and
reverse primer for the neomycin (Fig. 4B, lane 5) or hygromycin
ORF (Fig. S4A (i), lane 1) and 59-hygromycin fragment (Fig. S4A (i),
lane 3). This confirmed the presence of the neomycin/hygromycin
resistance gene. To confirm the correct targeting of the replacement
construct to the CYP5122A1 locus, a forward primer was designed
from the intergenic region upstream of CYP5122A1 gene that has
not been included in the replacement construct (Primer F2 59-
GTTGCGACTTACCTTCTACGTGTG-39; Fig. 4A). Two re-
verse primers were designed, one for each allele of the half knock
out. The first reverse primer corresponded to sequences in the
antibiotic resistance marker neomycin (Neo Internal Primer, 59-
CAAGGTGAGATGACAGGAGATC-39; Fig. 4A) or the hygro-
mycin resistance marker (Hyg Internal Primer, 59-CAAGCAC
TTCCGGAATCGGGC-39) used to replace the CYP5122A1 gene
and would identify the allele that has undergone homologous
recombination. To identify the other allele, we designed a reverse
primer (Primer P2 59-CCTTCTTCCACTGCTCATCC-39;
Fig. 4A) in the region of CYP5122A1 gene that has been replaced
on the corresponding allele and hence would only amplify
fragments from the intact allele. We therefore expected amplifica-
tion with primer pair F2/P2 only (Fig. 4C, lane 1) in the WT while
the HKO parasites would give positive PCR reactivity with both
F2/P2 as well as F2/Neo Int (Fig. 4C, lanes 3 and 4) or F2/Hyg Int
(Fig. S4A (ii)).
To check the functional output of knockout of one allele, cell
extracts from WT and HKO parasites were probed with anti-
CYP5122A1 antibody to detect the extent of CYP5122A1
expression. Significantly lower amount of CYP5122A1 was
expressed in the HKOs where replacement was made with the
neomycin cassette (Fig. 4D, lane 1, Fig. 4E) and the hygromycin
cassette (Fig. S4B, lane 2; S4C) as compared to WTs in respective
blots. This knockdown was specific for CYP5122A1 because HKO
parasites did not show any down-regulation of CYP710C1, another
CYP450 gene of Leishmania donovani that was used as a CYP450
control (Fig. S4D). Protein expression was further confirmed by
comparative fluorescence microscopy where staining intensity for
CYP5122A1 was lower in HKO cells (Fig. 4F, c–d) as compared to
WTs (Fig. 4F, a–b). To rule out the possibility of apparent higher
staining due to larger size of the cell, mean fluorescence intensity per
unit area per cell was measured microscopically. Fig. 4G shows the
mean fluorescence intensity per unit area of the stained cells where
the amount of CYP5122A1 staining in the HKOs/unit area was
significantly less as compared to the WTs.
To assess if the reduced expression of CYP5122A1 compro-
mised cellular physiology, various parameters were checked in the
HKO parasites. Morphologically, the HKOs were smaller in size
than their WT counterparts at all stages of the in vitro life cycle
(Fig. 5A). The division rate of the HKO cells was substantially
Figure 1. Structural analysis of CYP5122A1. A: Protein sequence
based schematic representation of CYP450 conserved motifs in
CYP5122A1 sequence. TM, Trans-membrane domain; PTG, Proton
transfer groove; SC, Stabilization core; HBL, Heme binding loop. B: A
ribbon representation of folded CYP5122A1 protein structure generated
using SWISS-MODEL server. a-helix, coiled ribbon; b-sheet, arrow;
random coil and loop, line. The motifs shown are, stabilization of the
core (pink) in the K helix; the proton transfer groove in central part of
the I-helix, mauve; heme binding loop, purple; conserved Cys (523),
indicated by an arrow.
doi:10.1371/journal.pone.0025273.g001
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slower than the WT cells showing a slower growth curve (Fig. 5B
and Fig. S4E). HKO parasites in general were less motile unlike
the highly motile WTs. Constitutive ROS level was higher in the
HKOs as compared to WTs (Fig. 5C) when measured on various
days of cycle. Impaired mitochondrial function in the HKOs was
evident from lower mitochondrial membrane potential (DYm) and
lower ATP levels as compared to WTs (Fig. 5D and E).
Mitochondrial Ca2+, a known inducer of the generation of DYm
as well as the utilization of the ATP [22] was also lower in the
HKO parasites (Fig. 5F). As evident from the above data, reduced
expression of CYP5122A1 in the promastigotes compromised
growth and mitochondrial function.
Knockdown of CYP5122A1 compromises the parasites
ability to infect both in vitro and in vivo
Next, we sought to compare the infective abilities of the WT
and the HKO parasites to assess if lesser CYP5122A1 expression
would impair the parasites’ ability to infect. Parasites containing
the pBSK+ Neo cassette as replacement of one allele of
CYP5122A1 showed reduced infecting abilities as compared to
WT cells in terms of attachment at 2, 4 and engulfment at 6 h
(Fig. 6A–C). Similarly, parasites containing the pBSK+Hyg
cassette also showed a reduced ability to infect (Fig. S4G; %
macrophages infected, control, 7466; hygromycin HKO, 2263,
n = 3, *P#0.05). The engulfed HKO parasites were cleared within
10 h of infection as suggested by the reduction in the number of
macrophages containing internal parasites (Fig. 6B). This could be
due to clearance by the macrophage generated ROS where HKO
parasites would be more susceptible to such stress. This is further
supported by the increased death of HKO promastigotes in vitro as
compared to WTs when exposed to H2O2 (Fig. S5A). To assess the
number of metacyclics in the inoculum of the HKO parasites to
see if low number of metacyclics reduced infective abilities, peanut
agglutinin based separation was used to isolate the infective forms.
Lower numbers of metacyclics were recovered from the HKO
cultures as compared to WT cultures (Fig. 7A) suggesting lesser
differentiation if one allele of CYP5122A1 was removed. When
the total number of metacyclics in the HKO inoculum was raised
by increasing multiplicity of infection, there was a moderate
increase in the number of macrophages infected but the infection
was comparatively lower than infection achieved with the WT
parasites (Fig. S5B). To investigate if the difference in infection
rate was only due to the lesser number of metacyclics in the HKO
cultures, macrophages were infected with equal numbers of
metacyclics alone, isolated from both the WT and the HKO
cultures. The infection pattern observed was similar to that
obtained with total cellular cultures (Fig. 7B–D). This clearly
showed that the HKO parasites cultures produced fewer
metacyclics that were comparatively less efficient to infect as
compared to metacyclics isolated from WT cultures.
Subsequently, to confirm the in vitro infection data in vivo,
hamsters were used as a model system. Eight weeks after parasite
administration to adult hamsters, significant splenomegaly was
observed in animals infected with WT parasites as compared to
the spleens in hamsters infected with HKO parasites as reflected in
the comparative spleen weight (Fig. 7E). In consonance with the
above observations, microscopic counts of splenic smears from
HKO infected hamsters showed lesser number of macrophages
containing parasites whereas splenic smears from WT parasite
infected hamsters showed a large number of macrophages loaded
with parasites (Fig. 7F). This data suggested that in the absence of
full constitutive expression of CYP5122A1, the parasites demon-
strated a compromised ability to infect both in vitro and in vivo.
Knockdown of CYP5122A1 alters the parasites ability to
withstand drug pressure
In the absence of vaccines, the treatment of visceral leishmaniasis has
centred around several drugs like sodium stibogluconate (pentavalent
antimony), amphotericin B and more recently, miltefosine [23]. The
HKO parasites showed increased susceptibility to potassium antimony
tartrate (PAT) the active form of pentavalent antimony and miltefosine
(Fig. 8A–B, Fig. S4F) suggesting a role of CYP5122A1 in drug
response. Therefore, based on the aforementioned results, WT
parasites were checked for cellular level of CYP5122A1 after drug
treatment. PAT was unable to induce any change in CYP5122A1
levels (Fig. 8C, (i) and (ii) whereas miltefosine was able to induce an up-
Figure 2. Expression of CYP5122A1 in amastigotes and promastigotes of L. donovani. A: Western blot analysis of equal protein quantities
from whole cell lysates prepared from L. donovani amastigotes (A) and promastigotes (P) probed with anti-CYP5122A1 antibody. B: Western blots of
total cell lysates prepared from L. donovani promastigotes at different time points during an in vitro growth cycle, probed with anti-CYP5122A1
antibody. Loading was normalized with Tubulin–a (50 kDa). C: Bar graph; right hand y-axis represents quantitation of immunoblots shown in B, mean
6 SE, n = 3. Line graph, left hand y-axis represents the number of metacyclic parasites formed during the in vitro growth cycle. D: Western blot
analysis of whole cell lysates prepared from L. donovani metacyclic prepared from logarithmic (L) and stationary (S) phase culture probed with anti-
CYP5122A1 antibody indicating marginal up-regulation of CYP5122A1.
doi:10.1371/journal.pone.0025273.g002
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regulation of CYP5122A1 at doses of 10–40 mM (Fig. 8D, i and ii) with
maximal induction at 24 h with 20 mM of miltefosine (Fig. 8D, iii).
Multiple drugs act via generation of ROS [24–25]. ROS levels
measured after miltefosine exposure showed increased ROS in both
the WT and the HKOs, generation in the HKOs being higher
(Fig. 8E). Scavenging this ROS with the antioxidant N-acetyl cysteine
(NAC, 20 mM), resulted in a substantial reduction of cell death in the
HKOs (cell death %, control, 260.3; HKO, 3564.0; HKO+NAC,
1561.0, n=3) suggesting that ROS generation was linked to drug
efficacy. Therefore, the above observations strongly imply that a
normal complement of CYP5122A1 is required by the Leishmania
parasite for defense against drugs.
Figure 3. Subcellular localization of CYP5122A1. A: Western blot of aqueous (Aq) and detergent (Det) phases of Triton X-114 extracts of
Leishmania promastigotes probed with anti-CYP5122A1 antibody. B: Photomicrographs of Leishmania donovani promastigotes stained with anti-
CYP5122A1 antibody and organelle specific markers. BIP & ER Tracker Blue-White DPX, ER marker; MitoTracker Red, mitochondrial marker; GAPDH,
glycosome marker. a: Nomarski; b: cells stained with anti-CYP5122A1 antibody; c: cells stained for organelle specific marker; d: merge of b and c; e:
mask of colocalization for d. Scale represents 10 mm.
doi:10.1371/journal.pone.0025273.g003
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Figure 4. Generation of CYP5122A1 half knock-outs. A: Schematic representation of replacement construct inserted into the genome with
positions of primers used for confirmation marked by arrows. 59: 59 homologous sequence; 39: 39 homologous sequence; Neomycin: ORF encoding
for resistance to neomycin; F2: forward primer designed in the intergenic region upstream of CYP5122A1 gene; P2: internal primer in CYP5122A1
encoding sequence that has been replaced in the replacement construct; NI: primer designed in the internal sequence of ORF for neomycin
resistance; Neo: primer pair amplifying neomycin resistance ORF, 59-Neo: Primers that amplify sequence spanning the 59 homologous region through
to the end of neomycin resistance ORF. B: Insertion of allelic replacement construct was confirmed by PCR for neomycin and knockout-neomycin
construct (59-Neo) using primers that span the 59 homologous sequence (Forward primer) and the neomycin gene (Reverse primer). Lane 1: positive
control (Pos) for neomycin resistance gene (plasmid); Lane 2: fragment obtained after amplification of neomycin resistance gene from genomic DNA
(G DNA); Lane 3: 1 kb DNA Ladder; Lane 4: Positive control for knock out–neomycin construct (plasmid); Lane 5, Fragment amplified for the knockout-
neomycin construct. C: Confirmation of insertion of the replacement construct at the correct locus was assessed by PCR. Lane 1: amplicons generated
from WT genomic DNA as template with primers F2/P2 indicating the presence of intact CYP5122A1 allele; Lane 2: Primers F2/NI did not generate any
amplicons with WT genomic DNA as template, showing the absence of neomycin resistance ORF; Lane 3: amplicons generated from HKO genomic
DNA as template with primers F2/P2 indicating the presence of an intact CYP5122A1 allele; Lane 4: amplicons generated from HKO genomic DNA as
template with primers F2/NI indicating the presence of insertion of neomycin resistance ORF at the correct locus. D: Western blot analysis of cell
lysates from WT and HKO parasites probed with anti-CYP5122A1 antibody showing decreased level of CYP5122A1 protein in the HKO parasites.
Loading was normalized with Tubulin–a (50 kDa). E: Bar graph representing averaged densitometric analysis of immunoblots represented in D
(mean6 SE, n = 3), * P#0.05. F: Photomicrographs of L. donovani WT (a, b) and HKO (c, d) parasites immunostained with anti-CYP5122A1. Scale,
10 mm. G: Bar graph representing mean fluorescence intensities of CYP5122A1 fluorescence in WT versus HKO parasites (mean6 SE, n = 3), * P#0.05.
doi:10.1371/journal.pone.0025273.g004
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Complementation of CYP5122A1 rescues phenotype
HKO parasites were complemented with WT copy of
CYP5122A1 through episomal expression with the pXG-GFP+2
vector (expressing the CYP5122A1 gene). Fig S6A shows the
presence of mRNA for CYP5122A1 in the transfected cells and
the presence of the fusion protein was demonstrated by western
blot and flow cytometry (Fig. S6B, C). The complementation
resulted in rescue of morphology from shorter HKO cells to
elongated forms resembling WTs (Fig. S6D). When drug
susceptibility of the HKO parasites was compared to the parasites
Figure 5. Morphology and biochemistry of HKO parasites. A: Photomicrographs of L. donovani WT and CYP5122A1 HKO cells during in vitro
growth cycle. Scale 5 mm. B: Growth pattern of WT and HKO parasites in vitro over a period of 6 days in culture. Mean 6 SE, n = 3. C: Comparison of
average constitutive levels of intracellular ROS in WT and HKO parasites. Mean6 SE, n = 3, * P#0.05. D: DYm measured by the potentiometric probe
JC-1. Mean 6 SE, n = 3; * P#0.05. E: Bar graph showing the basal level of ATP produced by the WT and the HKO cells. Mean 6 SE, n = 3; *P#0.05. F:
Bar graph shows mitochondrial Ca2+ levels. Mean 6 SE, n = 3; * P#0.05.
doi:10.1371/journal.pone.0025273.g005
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Figure 6. In vitro infective abilities of WT and HKOs. A. Photomicrographs of macrophage infected with WT and HKO parasites for different
time points. b: 1 h; d: 2 h; f: 4 h; h: 10 h; a, c, e, g: nomarski of b, d, f, h respectively. Scale, 5 mm. P: promastigote, A: amastigote. B. Bar graph
showing percentages of macrophages infected with WT and HKO parasites. Mean 6 SE, n = 3, * P#0.05. C. Number of parasites present in infected
macrophages over a period of time. Mean 6 SE, n = 3, * P#0.05.
doi:10.1371/journal.pone.0025273.g006
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with CYP5122A1 complementation, the complemented parasites
were comparatively more resistant to drugs as compared to the
HKOs but not as efficient as WTs to resist drug induced death
(Fig. S6E). This fusion protein also localized in the ER of the
parasites as seen by a co-localization with ER Tracker blue white
DPX stain (Fig. S6F).
Changes in ergosterol occur with alterations in
CYP5122A1 levels
Since several CYP450s are functionally related to sterol
biosynthesis [26], the HKOs carrying one allele of CYP5122A1
were checked for ergosterol content. HKO parasites expressed 3.5
Figure 7. HKOs are impaired in metacyclogenesis and their ability to infect in vivo. A. Number of WT and HKO metacyclics during in vitro
life cycle represented by bar graph. Mean 6 SE, n = 3, * P#0.05. B: Bar graph showing percentages of macrophages infected with WT and HKO
metacyclics at an MOI of 1:10. Mean 6 SE, n = 3, * P#0.05. C: Number of parasites present in infected macrophages when infection was carried out
with equal number of WT and HKO metacyclics. Mean 6 SE, n = 3, * P#0.05. D: Photomicrographs of macrophage infected with metacyclics (arrows)
isolated from WT and HKO parasite cultures. Scale, 10 mm. E: Bar graph shows spleen weights of hamsters infected for 8 weeks. Control: uninfected
hamsters; WT: hamsters infected with WT parasites, HKO: hamsters infected with HKO parasites. Mean 6 SE ,n = 3, * P#0.05. F. Infected macrophage
numbers represented as the number of infectious foci per field in splenic smears from hamsters infected with WT (WT) and HKO parasites (HKO). Data
represents mean 6 SE, n = 5; in which 10 different fields were analysed. * P#0.05.
doi:10.1371/journal.pone.0025273.g007
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Figure 8. Effect of drug exposure. A: Bar graph shows percentage viability of WT and HKO parasites in response to treatment with PAT. Mean 6
SE, n = 4; * P#0.05. B: Bar graph shows percentage viability of WT and HKO parasites in response to treatment with miltefosine. Mean 6 SE, n = 4;
* P#0.05. C.Western blot analysis (i) and its quantitation (ii) of total cell lysate from Leishmania donovani promastigotes post treatment with different
doses of PAT (100 mg/mL, 200 mg/mL and 300 mg/mL) for 24 h probed with anti-CYP5122A1 antibody. D. (i) Western blot analysis of Leishmania total
cell lysate post treatment with different concentrations of miltefosine for 24 h, (ii) quantitation of immunoblots in (i); (iii) western blot analysis of
L. donovani whole cell lysate upon treatment with 20 mM miltefosine for different time periods. Mean 6 SE, n = 4. E. Levels of intracellular ROS in
response to treatment with miltefosine measured using the fluorogenic probe CMH2DCFDA. Mean 6 SE, n = 3.
doi:10.1371/journal.pone.0025273.g008
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times lesser ergosterol than the WTs as evident from GC-MS
based analysis of organic solvent extracts of the cells (Fig. 9A).
Although it is not known if the Leishmania parasite can incorporate
ergosterol in vitro, a related kinetoplastid parasite, Trypanosoma brucei
takes up sterol precursors in the host [27]. Ergosterol supplement-
ed in vitro during Leishmania culture showed an uptake of ergosterol,
and a higher HKO parasite growth rate in contrast to those
cultured without ergosterol supplementation (Fig. 9B). Presence of
a higher level of ergosterol in CYP5122A1 complemented HKO
parasites indicated CYP5122A1 involvement in maintaining
ergosterol levels, although the extent of recovery was not
equivalent to the WTs (Fig. 9A). The alteration of sterol levels
could have important implication in drug response because
ergosterol is required for action of some drugs. For example,
amphotericin B, a polyene antifungal drug also used for the
treatment of leishmaniasis [1] associates with ergosterol for its
action [28], arguably therefore, cytotoxic effect of amphotericin B
would be lesser in the HKO parasites. There was a distinct
lowering of amphotericin B cytotoxicity in CYP5122A1 HKOs in
comparison to the WTs (Fig. 9C) as evident from the percentage
viabilities. Therefore, this data clearly indicated that deficiency in
CYP5122A1 resulted in lowering of ergosterol levels consequently
making them less susceptible to amphotericin B.
Discussion
Cytochrome P450s are an important group of proteins involved
in the synthesis of physiologically active compounds, drug
Figure 9. Synthesis of ergosterol in HKO and WT parasites. A. Chromatogram of ergosterol profile from sterol extracts of WT, HKO and CMPL
strains subjected to GC-MS analysis. Insets. Table showing the approximate ergosterol content as calculated using a standard curve. TLC analysis of
ergosterol from WT (Lane 1), HKO (Lane 2) and complemented parasites (Lane 3). Rf value of ergosterol: 0.588. Standard ergosterol dilutions (Lane 4:
0.05 mg, Lane 5: 0.1 mg, Lane 6: 0.5 mg, Lane 7: 1 mg). B. Comparative growth pattern of WT and HKO parasites in vitro over a period of 6 days in
culture, in the presence and absence of ergosterol. Mean 6 SE, n = 3. C. Bar graph shows percentage viability of WT, HKO and CMPL parasites in
response to treatment with amphotericin B for 6 h. Mean 6 SE, n = 3.
doi:10.1371/journal.pone.0025273.g009
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metabolism and bioconversion of xenobiotics. Although the
parasite genome database annotations identify 3 distinct CYP450s
in Leishmania donovani, no data is available on the possible functions
of these proteins in this medically important parasite. Both from
the point of view of identifying drug targets and understanding the
physiology of the Leishmania parasite, CYP450s need to be
investigated. In this study, we report the involvement of one of
the CYP450s, the CYP5122A1 in the survival and function of the
Leishmania donovani parasite.
The sequence of the cloned CYP450 from L. donovani obtained
using primers designed from L. major showed the presence of
signature motifs of CYP450 proteins. Designated CYP5122A1 by
the CYP450 Nomenclature Committee, the sequence of the
protein showed close identity within the subgroup of Leishmania but
shared ,50% identity with the Trypanosoma sequences. For
functional studies, the free-swimming L. donovani promastigotes
were selected as an ideal model system to analyse the function of
CYP5122A1 because promastigotes differentiate into infective
metacyclics that eventually infect mammalian macrophages. No
significant alterations in the CYP5122A1 levels during in vitro life
cycle suggested constitutive levels to be sufficient for growth and
metacyclogenesis. However, the higher expression of the protein in
stationary phase metacyclics as compared to the log phase ones
implied that accumulation of this protein was coincident with
increase in infective abilities of the parasites. Interestingly, the
intracellular amastigotes also expressed a higher quantity of the
protein than promastigotes. The requirement of CYP5122A1 for
normal growth of the parasite was substantiated by impaired
differentiation and growth of the HKO parasites where one allele
of CYP5122A1 was replaced by antibiotic resistance resulting in
expression of half the amount of the protein as is present in the
WTs. When HKO parasites were transfected to episomally express
CYP5122A1 to compensate the reduced expression in them,
improved growth as compared to the HKOs further validated the
requirement of CYP5122A1 for development of the parasite. The
sharp decline in ergosterol levels in the HKO parasites coupled
with their inability to tolerate oxidative stress indicated that the
lowered ergosterol could be a reason for lesser parasite growth and
lack of resistance to drug-induced stress. While the improved
growth rate upon supplementation of ergosterol could be looked
upon as an indication of a positive role of the sterol, the HKO
parasites episomally expressing CYP5122A1 showing increased
ergosterol content and improved growth rate further confirmed
the importance of ergosterol. In another kinetoplastid parasite, the
Trypanosoma spp. alterations in ergosterol levels through enzymatic
inhibition induce reduction in cell growth [29–30]. Although
Leishmania parasites can survive with lower sterol levels, normal
supplement of sterol is required for optimal parasite function [17]
which is reinforced by this study. Since sterol biosynthesis
inhibitors are projected as attractive drug targets [16,31], lower
ergosterol in the HKOs suggest a link of CYP5122A1 to sterol
biosynthesis which makes a strong case for CYP5122A1 to be
investigated further for evaluation as a possible drug target.
Efficient ability to bind to the macrophages and invade the cells
determines the extent of infection and finally, disease pathogenesis.
Reduced infective ability of the HKO parasite when compared to
WT parasite could be due to several reasons. Firstly, reduced
infectivity could be related to lower number of infective forms
present in the HKO parasite inoculum, secondly, defects in host-
parasite membrane interaction or thirdly, a rapid parasite
clearance by host generated ROS. The lower recovery of
metacyclics from the HKO cultures as compared to the WT
cultures indicated that formation of fewer metacyclics could be a
reason for lower infectivity. Since metacyclics from HKOs were
less efficient for infection as compared to the WT metacyclics, the
quality of their membrane could also be a reason for impaired
ability to infect. Therefore, it is likely that a combination of factors
like lesser number of infective forms in a given inoculum and
defective membrane fusion events were responsible for lower
infection rate by the HKO parasites. Altered lipid composition of
membranes is known to affect membrane binding events in
general like in yeast where ergosterols play an important role in
plasma membrane fusion [32–33]. HKO parasites expressing low
ergosterol were cleared faster by the host possibly because of
compromised resistance to oxidative stress as sterols are proposed
to be crafted by natural selection as an early defense mechanism to
ROS [15]. The notion that parasites with low ergosterol are
vulnerable to oxidative stress is further supported by increased
susceptibility of these parasites to H2O2 induced stress in vitro.
Since the extent of sterol oxidation is defined by the sterol content
itself, the low ergosterol cells would be prone to increased ROS
induced damage [34].
As low CYP5122A1 levels in the HKO parasites increased
oxidative stress susceptibility, it was of interest to investigate how
the WT parasites expressing normal CYP5122A1 levels handled
drug exposure. The WT parasites resisted lower doses of
miltefosine more efficiently because they could up-regulate
CYP5122A1 in response to the drug. Altered lipid content by
the action of miltefosine [35–36] combined with increased
miltefosine-generated ROS increased the susceptibility of the
HKO parasites to the drug. It was obvious that ROS played a
major role in miltefosine induced cell death because presence of an
antioxidant during miltefosine exposure protected the cells. In
contrast, PAT treatment could not induce CYP5122A1 increase
and caused higher death. Although the difference in response
could be due to the dissimilar mode of action, these observations
lend credence to the suggestion that CYP5122A1 levels are critical
for combating drug effects. Arguably, drugs using cellular sterols to
exert their action should show impaired effects in the HKO cells
with lower ergosterol. Consistent with this view, HKO parasites
were less susceptible to amphotericin B, an anti-leishmanial drug
that requires association with membrane ergosterol for action
[9,18]. This provides an important possibility that CYP5122A1
deficiency could be linked to resistance to amphotericin B as
changes in sterol profile is known to accord amphotericin B
resistance [9,18].
The mitochondria primarily sequesters Ca2+ to stimulate and
control the rate of oxidative phosphorylation to induce mitochon-
drial permeability transition, regulate cytosolic Ca2+ pulses and
drive apoptotic cell death [22]. The partially functional mito-
chondria, with the lower DYm, low ATP production, low Ca
2+
and higher ROS generation in HKO parasites possibly reflected
consequences of lower ergosterol content as well because
ergosterol is found in the membranes of intracellular organelles
including Leishmania mitochondria [37].
The close similarity in CYP5122A1 sequences between the old
and the new world Leishmania spp. with the conserved heme
binding domain suggest commonality of function with its
orthologues in the Leishmania and Trypanosoma species. Therefore,
how can this data be integrated in a model of Leishmania survival?
The information obtained clearly establishes that interference with
CYP5122A1 levels have deleterious consequences for the parasite
in terms of compromised organellar function, increased suscepti-
bility to drugs and impairment of the ability to infect, firmly
establishing CYP5122A1 as an essential protein for Leishmania
survival. Therefore, it would be of interest to check the status of
this protein in Leishmania field isolates from endemic regions to
relate if alterations of this protein is linked to drug resistance. The
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data presented here strongly suggests that CYP5122A1 could be a
possible drug target as it is functionally important for parasite
survival and does not share identity with host CYP450s making it
amenable to interception. Moreover, this protein could play an
important role in resistance to drugs that use sterols to exert their
effects, for which the levels of this protein in drug resistant isolates
from endemic areas needs to be investigated.
Materials and Methods
Reagents
ERTrackerTM Blue-White DPX, MitoTrackerH Red, Rhod –
2AM, JC-1 (5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazo-
lylcarbocyanineiodide), CM-H2DCFDA, SYTO 11 Green, ATP
determination kit and pluronic acid were obtained from Molecular
Probes (Eugene, OR). pGEM-TEasy vector system was procured
from Promega (Madison, WI). Trizol, First strand c-DNA
synthesis kit and Hi-fidelity Taq polymerase were from Invitrogen
(Carlsbad, CA). Restriction enzymes, dNTPS, Quick ligase, T4
DNA ligase, and Taq polymerase were from New England
BioLabs (Beverley, MA). Miltefosine was purchased from Cayman
Chemicals (Ann Arbor, MI). Potassium antimony tartrate (PAT),
Dulbecco’s Modified Eagles Medium (DMEM), ergosterol, peanut
agglutinin, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide), triton-X-114, amphotericin B, BSTFA (N,O-bis
(trimethylsilyl) trifluoroacetamide), TMCS (trimethylchlorosilane),
foetal bovine serum and genomic DNA isolation kit were obtained
from Sigma Aldrich. Western blotting reagents and enhanced
chemiluminescence kit were from Amersham Life Sciences
(Piscataway, NJ). CB-XTM Protein assay kit was obtained from
G-Biosciences (Maryland Heights, MO). Silica G plates were from
Analtech Inc. (Newark, DE). Peptides were commercially
synthesized by USV Peptides Ltd. (Bangalore, India). All other
chemicals, unless otherwise specified, were from Sigma Aldrich.
Antibodies
Anti-CYP5122A1 antibody was raised in rabbits using a peptide
specific for the CYP5122A1 protein (Gly-Pro-Arg-Gly-Val-Pro-
Ser-Val-Asn-Asp-Val-Arg-Asp-Leu). This stretch was selected for
raising antibodies for its high antigenicity, hydrophobicity, the
presence of coils in the secondary structure and sequence
specificity for CYP5122A1 distinct from the other CYP450s
annotated in the Leishmania spp. database. Similarly antibody was
also raised against another CYP450 of L. donovani, CYP710C1
using the peptide (Cys-Asp-Glu-Lys-Thr-Val-Val-Pro-Lys-Gly-
Met-Ile). Rabbit anti-tubulin-a antibody was obtained from
Neomarker (Fremont, CA). Anti-BIP antibody was a kind gift
from Dr. J. D. Bangs, University of Wisconsin (Madison, WI).
Secondary antibodies conjugated to Alexa Flour 488 and 594 and
horse radish peroxidase were obtained from Invitrogen (Carlsbad,
CA) and Jackson Immunoresearch Laboratories (West Grove, PA)
respectively. Anti-GAPDH was from Santa-Cruz Biotechnology
(Santa Cruz, CA).
Animals
Syrian hamsters (Mesocricetus auratus), 3–6 weeks old, were used
for in vivo infection.
Ethics statement
All procedures in this study were carried out as per the
guidelines laid down by the ‘‘Institutional Animal Ethics
Committee’’ of the National Institute of Immunology, New Delhi.
The protocol for this specific study was approved by the same
committee via permit no. IAEC/168/07. This study was also
approved by the ‘‘Institutional Biosafety Committee’’ via permit
no. IBSC110#07.
Cells, treatments, extraction and MTT assay
Leishmania donovani promastigotes, amastigotes and J774A.1
murine macrophages (ATCC No. TIB-67) were cultured as
described earlier [6,7,38]. Metacyclics were isolated by incubating
107 cells in 100 mg/mL peanut agglutinin (PNA) and cells non-
adhered to PNA (metacyclics) were separated by centrifugation
[21]. To study effects of drugs, parasites in the logarithmic phase
were treated with different doses of miltefosine (10 mM to 40 mM),
potassium antimony tartrate (100–300 mg/mL) and amphotericin
B (1–2.5 mg/mL). For extraction of membrane proteins, cells were
resuspended in 0.5% Triton X-114, homogenized and incubated
on ice for 90 mins. The insoluble material was removed by
centrifugation and the supernatant was incubated at 37uC for one
hour following which the aqueous and detergent phases were
separated. Ergosterol was added to culture medium at a final
concentration of 3 mg/mL. To estimate cytotoxicity, MTT assay
was carried out as described previously [38].
Cell lysates, SDS-PAGE and western blotting
Cell lysis was performed in a lysis buffer (0.125 M Tris HCl,
(pH 6.8) 4% SDS, 20% v/v glycerol, 10% b-mercaptoethanol)
and protein content was quantitated using CB-XTM Protein Assay
Kit. SDS PAGE, western blots and densitometry were carried out
as described previously [6,38]. For western blots, antibodies were
used at various dilutions; anti-CYP5122A1 antibody (1:20,000),
anti-tubulin-a antibody (1:10,000), secondary antibodies (1:20,000
dilutions). Reactivity was visualized by enhanced chemilumines-
cence.
Cloning, sequencing and analysis
Overlapping sets of primers for the CYP450 protein genes were
designed from sequence available with the Leishmania major genome
database (LmjF27.0090, Gene DB hosted by the Wellcome Trust
Sanger Institute, Hinxton, UK). Using L. donovani genomic DNA
as template, an insert was amplified with relevant primers and
cloned into pGEM-TEasy vector. Sequencing was carried out by
the di-deoxy method [39], at sequencing facility of Delhi
University (New Delhi, India). The sequence was submitted to
the CYP450 Nomenclature Committee [19] (http://drnelson.
uthsc.edu/cytochromep450.html) for assignment. Alignment of
the L. donovani sequence with other CYP450s was performed using
ClustalW hosted at the European Bioinformatics Institute [40].
The protein sequence derived was subjected to secondary structure
prediction program PSIPRED hosted at the Bloomsburry Center
for Bioinformatics [41]. The derived protein sequence of
CYP5122A1 was also submitted to the SWISS-MODEL homol-
ogy modelling server hosted at the Swiss Institute of Bioinformatics
[42]. The model generated was viewed in Pymol molecular
graphic software (educational use). The stereochemical qualities of
this 3D model were checked using Ramachandran plot [43]
generated by PROCHECK (EMBL-EBI, UK) (http://www.ebi.
ac.uk/thornton-srv/software/ PROCHECK/). WHATCHEK
(http://www.cmbi.kun.nl/gv/whatcheck/) server was used to
assess the packing quality of the protein model [44].
For CYP5122A1 allelic replacement constructs, ORFs encoding
neomycin and hygromycin resistance were inserted between
0.4 kb of 59 and 0.37 kb of 39 of CYP5122A1 homologous
regions in the pBlueScript SK+ vector to generate the constructs
pBSK+CYP5122A1Neo and pBSK+CYP5122A1Hyg respective-
ly. Half knockouts (HKOs) were generated with these constructs
through transfection of log phase promastigotes as described
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previously [38]. To generate double knockout parasites, second
allelic replacement construct was transfected into the HKO
parasites. Proper insertion of cassettes was confirmed by PCR to
detect the presence of replacement constructs into the transfor-
mant genomic DNA. Primers were also designed using the
intergenic sequence upstream of CYP5122A1 gene, the antibiotic
resistance marker ORFs and the CYP5122A1 gene, such that
amplification using these primers of expected molecular weight
would only occur upon insertion at the correct locus. The
leishmanial expression vector pXG-GFP +2 (a kind gift from Dr.
S. Beverley) containing the CYP5122A1 gene was used for
complementation of CYP5122A1 through episomal expression in
the HKO parasites. Complementation was confirmed by GFP
expression and detection of fusion m-RNA and GFP-fusion
protein in the transformants.
Immunocytochemistry and growth curve
Fixed (2% formaldehyde), digitonin or saponin (0.01%)
permeabilized cells were stained using rabbit anti-CYP5122A1
antibody (1:500) followed by labelling with Alexa Fluor 488
conjugated secondary antibody (1:750). For co-localization,
MitoTrackerH Red (0.5 mM/106 cells) was used to visualize
mitochondria while ER-TrackerTM Blue-White DPX (1 mM/106
cells), anti-BIP antibody (1:1000) were used to identify the
endoplasmic reticulum (ER). Anti-GAPDH antibody (1:50) was
used to identify glycosomes. Stained cells were analysed with a
Nikon Eclipse TE2000E microscope (Nikon, Japan). FACS
Calibur (Becton Dickinson, NJ) equipped with a 488 nm air
cooled argon ion laser was used for flow cytometric analysis as
described previously [45]. Mean fluorescence intensities per unit
area of WT and HKO cells stained with anti-CYP5122A1
antibody were measured using the software ImagePro Plus (Media
Cybernetics). For growth curve, equal number of cells (107 or
56106) was plated and cell numbers analysed by haemocytometer
based counting every 24 h.
Measurement of DYm, Ca
2+, ROS and ATP
Ca2+ and DYm was measured using Rhod-2 AM and JC-1 as
probe as described previously [6]. For measurement of ROS, the
cells (107) were loaded with the cell permeant probe CM-
H2DCFDA (2 mg/mL) as described previously [6] and fluores-
cence measurements were taken at 507/530 nm using a FluoStar
Optima fluorescence reader (BMG Labtechnologies Inc., Ger-
many). ATP was measured in a reaction buffer containing 1 mM
dithiothreitol, 0.5 mM luciferin and 12.5 mg/mL luciferase using a
Fluostar Omega multi-label detection system as described
previously [6].
Infection
In vitro Leishmania-macrophage infection was carried out as
described previously [7] at a parasite: macrophage ratio of 10:1.
For in vivo infection, Syrian golden hamsters were injected intra-
cardially with 108 parasites in stationary phase of growth. After 8
weeks, the animals were euthanized and spleen slices were used to
prepare splenic smears. Smears were stained with Giemsa stain
and scored for infected macrophages.
Estimation of ergosterol
Sterols were isolated as described by Arthington-Skaggs et al.
[46], with slight modifications. Briefly, cells were suspended in
25% alcoholic KOH and incubated at 85uC (1 h) followed by
cooling to room temp and addition of sterile distilled water and n-
heptane mixture. Standard ergosterol dilutions and sterol
extraction samples from WT, HKO and complemented strain of
parasites were spotted on a Silica Gel G plate, resolved using a
binary solvent (hexane/ethyl acetate (75/25)) and visualized using
Mo’s stain (12.5 g of ammonium molybdate (VI) tetrahydrate,
5.0 g of ammonium cerium (IV) sulphate, 50 ml of concentrated
sulfuric acid volume raised to 500 mL with water). For GC-MS,
the sterol extracts were dried under nitrogen gas, resuspended in n-
hexane and derivatized with BSTFA containing 1% TMCS at
70uC for 1 h. The derivative mixture was dried under nitrogen to
remove excess BSTFA and subsequently re-dissolved in n-hexane.
Agilent 7890A gas chromatography instrument coupled to an
Agilent 5975C mass spectrometer and an Agilent ChemStation
software (version G1701EA, Agilent Technologies, Palo Alto, CA)
was used for GC-MS. For separation, a HP-5MS capillary column
(30 m60.25 mm i.d) was used with the column temperature was
set at 100uC (held for 5 min for injection) programmed at
20uC min21 to 200uC (held for 10 min, followed by 10uC min21
to 230uC) and finally at 5uC min21 to 320uC (5 min). Injection
temperature was set at 260uC. High purity helium was used as
carrier gas of 1.0 mL min21 flow-rate. The spectrophotometers
were operated in electron-impact (EI) mode, full scan of 40–
550 amu or selected ion monitoring (SIM) was used, the ionization
energy was 70 eV. Calibration curve was generated using n-
hexane stock solutions of standard ergosterol dilutions (5- 500 ng/
mL) in duplicates and plotting the peak area versus the
concentration.
Statistical analysis
Data were analysed by student’s unpaired t-test. Values were
considered significantly different at P#0.05. All experiments were
repeated 3–4 times. Data are expressed as the mean 6 SE of
several independent experiments.
Supporting Information
Figure S1 Phylogenetic analysis of CYP5122A1. A phylo-
gram generated from CYP450-like sequences analysed by
ClustalW showing distances between CYP450-like proteins of
various species. Scale represents 0.06 nucleotide substitutions per
site.
(TIF)
Figure S2 Predicted secondary structure. Schematic
representation of the predicted secondary structures in and around
the active site generated using the PSIPRED server hosted at the
Bloomsburry Centre for Bioinformatics (University College,
London and Birkbeck college). PTG, Proton transfer groove;
SC, stabilization core; HBL, Heme binding loop are highlighted in
yellow. Active site cysteine indicated by arrow.
(TIF)
Figure S3 Ramachandran plot of CYP5122A1. Ramachan-
dran plot generated for CYP5122A1 protein structure modelled
using SWISS-MODEL shows majority of the residues to fall into
the favourable region of the plot.
(TIF)
Figure S4 Analysis of pBSK+CYP5122A1-Hyg HKO. A: (i)
Insertion of allelic replacement construct into the genomic DNA
was confirmed by PCR for hygromycin and knockout-hygromycin
construct using primers that span the 59 homologous sequence
(Forward primer) and the hygromycin gene (Reverse primer).
Lane 1: fragment amplified for the hygromycin resistance gene;
lane 2: 1 kb DNA ladder; lane 3: fragment amplified for the knock
out hygromycin construct. (ii) Confirmation of insertion of the
replacement construct at the correct locus was assessed by PCR.
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Lane 1: amplicons generated from HKO genomic DNA as
template with primers F2/P2 indicating the presence of an intact
CYP5122A1 allele (primer positions indicated in schematic in
Fig. 4A); Lane 2: amplicons generated from HKO-Hyg genomic
DNA as template with primers F2/HI indicating the presence of
insertion of hygromycin resistance ORF at the correct locus. B:
Western blot analysis of cell lysates from WT and HKO parasites
with anti-CYP5122A1 antibody showing the decreased level of
CYP5122A1protein in the HKOs. Loading was normalized with
Tubulin–a (50 kDa). C: Bar graph representing averaged
densitometric analysis of immunoblots represented in B, mean6
SE, n= 3. D: Western blot analysis of cell lysates from WT and
HKO parasites using anti-CYP710C1 antibody showing equal
levels of the CYP710C in the WT and the HKO parasites.
Loading was normalized with tubulin-a (50 kDa). E: Comparison
of growth and survival of WT and HKO parasites in vitro over a
period of 6 days in culture. Mean 6 SE, n = 3. F: Bar graph
showing percentage viability of WT and HKO parasites in
response to treatment with PAT. Note the increased susceptibility
of HKOs as compared with WT. Mean6 SE, n = 4; * P#0.05. G:
Photomicrographs of macrophage infected with WT and HKO
parasites stained with Syto 11 Green fluorescent nucleic acid stain.
a: nomarski image; b: Syto 11 Green stained image; c: merge of a
and b. Scale, 5 mm.
(TIF)
Figure S5 A: Bar graph shows percentage viability of WT and
HKO parasites in response to treatment with H2O2. Mean 6 SE,
n= 4; * P#0.05. B: Photomicrographs of J774A.1 macrophages
infected with WT and HKO L. donovani parasites at multiplicity of
infection at 1:25 and 1:50, stained with Syto 11 Green. Scale,
20 mm.
(TIF)
Figure S6 Effects of complementation of CYP5122A1 in
HKOs. A: Agarose gel (1.5%) showing expression of GFP-
CYP5122A1 fusion mRNA (GFP Forward primer & CYP5122A1
internal primer) in 2 clonally selected strains of CYP5122A1
complemented parasites. Lane 1: negative control; lane 2 & 3:
fusion product amplified from c-DNA prepared from comple-
mented parasites; lane 4: 1 kb DNA Ladder; lane 5: Positive
control amplified using pXG-GFP+2CYP5122A1 plasmid as the
template. B: Western blot analysis of lysates of HKO and CMPL
cells probed for the fusion protein show the presence of GFP-
CYP5122A1 protein at expected molecular weight of approxi-
mately 96KDa in lysates of complemented parasites. C: Flow
cytometric analysis of complemented parasites. D. Photomicro-
graphs of HKO (a) and complemented (b) parasites. Scale, 5 mm.
E: Bar graph showing percentage viability of WT, HKO and
complemented parasites in response to treatment with miltefosine
and PAT. Mean 6 SE, n = 4; * P#0.05. F: Photomicrographs of
CMPL promastigotes stained with anti-CYP5122A1 antibody and
ER-specific markers, ER Tracker Blue-White DPX. Scale, 5 mm.
(TIF)
Figure S7 Subcellular localization of CYP5122A1 in
metacyclic parasites Photomicrographs of Leishmania donovani
metacyclic parasites stained with anti-CYP5122A1 antibody and
ER-specific marker, BIP. Scale represents 10 mm.
(TIF)
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